Literature DB >> 19960199

Successful treatment with rituximab of one patient with CANOMAD neuropathy.

Emilien Delmont, P Y Jeandel, A M Hubert, L Marcq, J Boucraut, C Desnuelle.   

Abstract

We report a successful treatment with rituximab in a patient with CANOMAD neuropathy resistant to previous therapy. The titers of anti-disialosyl antibodies were decreased 3 months after the beginning of the treatment and the sensory ataxia clearly improved after 9 months of therapy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19960199     DOI： 10.1007/s00415-009-5412-z

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  11 in total

1.  Chronic ataxic neuropathy with cold agglutinins: atypical phenotype and response to anti-CD20 antibodies.

Authors:  K Siddiqui; E Cahalane; M Keogan; O Hardiman
Journal:  Neurology       Date:  2003-11-11       Impact factor: 9.910

2.  A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale.

Authors:  R C Graham; R A C Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03-30       Impact factor: 10.154

3.  The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies.

Authors:  H J Willison; C P O'Leary; J Veitch; L D Blumhardt; M Busby; M Donaghy; P Fuhr; H Ford; A Hahn; S Renaud; H A Katifi; S Ponsford; M Reuber; A Steck; I Sutton; W Schady; P K Thomas; A J Thompson; J M Vallat; J Winer
Journal:  Brain       Date:  2001-10       Impact factor: 13.501

4.  Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group.

Authors:  I S Merkies; P I Schmitz; F G van der Meché; P A van Doorn
Journal:  Neurology       Date:  2000-02-22       Impact factor: 9.910

Review 5.  The immunopathogenesis of Miller Fisher syndrome.

Authors:  H J Willison; G M O'Hanlon
Journal:  J Neuroimmunol       Date:  1999-12       Impact factor: 3.478

Review 6.  B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.

Authors:  Joerg-Patrick Stübgen
Journal:  J Neuroimmunol       Date:  2008-11-15       Impact factor: 3.478

7.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

8.  Do patients having a decrease in SNAP amplitude during the course of MMN present with a different condition?

Authors:  Emilien Delmont; Charles Benaïm; Mael Launay; Sabrina Sacconi; Marie-Hélène Soriani; Claude Desnuelle
Journal:  J Neurol       Date:  2009-07-30       Impact factor: 4.849

Review 9.  Clinical tools for assessing balance disorders.

Authors:  A Yelnik; I Bonan
Journal:  Neurophysiol Clin       Date:  2008-10-18       Impact factor: 3.734

10.  Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy.

Authors:  S Attarian; J Boucraut; A M Hubert; D Uzenot; E Delmont; A Verschueren; J Franques; J P Azulay; J Pouget
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-09-01       Impact factor: 10.154
View more
  11 in total

1.  Successful treatment of CANOMAD with IVIg and rituximab.

Authors:  Wolfgang N Löscher; Alexander Woertz; Monika Wallnöfer; Julia V Wanschitz; Gerhard Luef
Journal:  J Neurol       Date:  2013-02-12       Impact factor: 4.849

Review 2.  Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.

Authors:  Michael Pt Lunn; Eduardo Nobile-Orazio
Journal:  Cochrane Database Syst Rev       Date:  2016-10-04

Review 3.  Sustained response to subcutaneous immunoglobulins in chronic ataxic neuropathy with anti-disialosyl IgM antibodies (CANDA): report of two cases and review of the literature.

Authors:  D Marastoni; L Africa; G M Fabrizi; F Giannini; A Peretti; S Bocci; L Insana; S Ferrari; F Ginanneschi; G Zanette
Journal:  J Neurol       Date:  2020-04-28       Impact factor: 4.849

Review 4.  Clinical phenotype of patients with neuropathy associated with monoclonal gammopathy: a comparative study and a review of the literature.

Authors:  Abraham C J Stork; W-Ludo van der Pol; Hessel Franssen; Bart C Jacobs; Nicolette C Notermans
Journal:  J Neurol       Date:  2014-04-30       Impact factor: 4.849

Review 5.  An update on monoclonal gammopathy and neuropathy.

Authors:  Sindhu Ramchandren; Richard A Lewis
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

6.  CANOMAD responding to weekly treatment with intravenous immunoglobulin (IVIg).

Authors:  Martin Krenn; Geoff Keir; Udo Carl Wieshmann
Journal:  BMJ Case Rep       Date:  2014-04-10

7.  CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA).

Authors:  Rocio Garcia-Santibanez; Craig M Zaidman; R Brian Sommerville; Glenn Lopate; Conrad C Weihl; Alan Pestronk; Robert C Bucelli
Journal:  J Neurol       Date:  2018-04-09       Impact factor: 4.849

Review 8.  Diagnostic insights into chronic-inflammatory demyelinating polyneuropathies.

Authors:  Johannes J Roggenbuck; Joseph Boucraut; Emilien Delmont; Karsten Conrad; Dirk Roggenbuck
Journal:  Ann Transl Med       Date:  2018-09

9.  Facial Involuntary Movements and Respiratory Failure in CANOMAD, Responsive to IVIG Therapy.

Authors:  Kate Johnson; Ashish Malkan; Mohamed Shaffi
Journal:  Case Rep Med       Date:  2015-11-30

Review 10.  Paraproteinemic neuropathy: a practical review.

Authors:  Richard A Rison; Said R Beydoun
Journal:  BMC Neurol       Date:  2016-01-28       Impact factor: 2.474
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.